EN DE
Watch CRISM Therapeutics Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CRISM Therapeutics Corporation (CRTX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of CRISM Therapeutics Corporation stock £0.02, price £0.09, that is 71.6% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN VGG042401262

CT CRISM Therapeutics Corporation logo Thin data Nov 4, 2026

CRISM Therapeutics Corporation

CRTX · LSE
Very expensive, weak quality

Our calculation puts a fair price 72% below what the stock costs today.

Mixed Growth (revenue YoY +824.0 %/yr in GBP)
Fair value £0.0241 · Strongly overvalued (−71.6%)
Quality 35/100
Negative free cash flow
Trails peers (1/8)
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch CRISM Therapeutics Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£6.18 £0.0525 Fair Value £0.0241 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range £0.0525 – £6.18 · fair‑value band £0.0167 – £0.0241 · the £0.0850 price screens above the £0.0241 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow CRISM Therapeutics in your weekly email

Every Wednesday you see whether CRISM Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs.

Show moreShow less

Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the delivery of chemotherapy directly into cancer tissues. The company also offers formulation and consultancy services.

The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporation was founded in 2016 and is based in Road Town, the British Virgin Islands.

Stock analysis

CRISM Therapeutics Corporation (CRTX) currently trades at £0.0850, while our model-based Fair Value estimate is £0.0241, 72% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: £0.0167 (bear) to £0.0241 (bull), the price of £0.0850 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

CRISM Therapeutics Corporation reported revenue of £231K in FY2025 versus £0 in FY2021. Reported net income was −£1.9M in FY2025.

Key figures

Market cap £6.8M Micro · P/S ratio 32.6 · EPS (TTM) £−0.0500 · Dividend yield 0.6% · Return on equity −130% · Return on assets (EBIT) −42.3% (5-year average) · Operating margin −420% · Revenue (TTM) £231K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 51% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, CRTX screens richer than that median.

Fair Value models

Bear £0.0167 Fair Value £0.0241 Bull £0.0241
Price £0.0850 · Downside -71.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) £0.0100 £0.0200 £0.0200 53
All 1 models by family
Asset-Based
NCAV (Graham) £0.0100 £0.0200 £0.0200 53

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 79
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRTX screens overvalued: fair value 72% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CRISM Therapeutics Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −71.6% · Below median
Profitability
Return on assets −105.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Dividend yield (12 months) 0.6% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.78× · Priciest 25%
P/S (12 months) 29.31× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)12 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs CRTX
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs CRTX
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs CRTX
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs CRTX
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs CRTX
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs CRTX
argenx SE ARGX $927.21 $908.40 −2% vs CRTX
CSL Limited CSL A$202.04 A$183.04 −9% vs CRTX
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs CRTX
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs CRTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CRISM Therapeutics Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CRISM Therapeutics Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CRTX

Frequently asked questions

Is CRISM Therapeutics Corporation (CRTX) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of £0.0241 versus a price of £0.0850, about 72% lower (overvalued).
What is the fair value of CRTX?
Our model-based fair value for CRISM Therapeutics Corporation is £0.0241 (as of Nov 4, 2026), built from audited fundamentals. The current price: £0.0850.
What is the quality score of CRTX?
CRISM Therapeutics Corporation has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CRISM Therapeutics Corporation (CRTX)?
Our model-based price target is the fair value of £0.0241 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario £0.0167, optimistic scenario £0.0241. It is a calculation from audited fundamentals, not an analyst target.
What is the CRISM Therapeutics Corporation stock forecast for 2026?
Our models put fair value at £0.0241, about 72% lower versus a price of £0.0850 (overvalued). Cautious scenario £0.0167, optimistic scenario £0.0241. The calculation is refreshed regularly with new filings.
What is the revenue of CRISM Therapeutics Corporation (CRTX)?
CRISM Therapeutics Corporation reported trailing-twelve-month revenue of about £231K (latest available figure, as of Nov 4, 2026).
Does CRISM Therapeutics Corporation pay a dividend?
CRISM Therapeutics Corporation currently shows a dividend yield of 0.62% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of CRISM Therapeutics Corporation (CRTX)?
CRISM Therapeutics Corporation has a dividend yield of 0.6%.
What is the intrinsic value of CRISM Therapeutics Corporation (CRTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CRISM Therapeutics Corporation it is £0.0241 per share (as of Nov 4, 2026), against a price of £0.0850. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is CRISM Therapeutics Corporation stock overvalued or undervalued in 2026?
As of Nov 4, 2026, CRTX trades above its calculated fair value: price £0.0850, fair value £0.0241, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRTX?
No. The price is what the market pays today (£0.0850); the fair value is what the company's own numbers justify (£0.0241). For CRISM Therapeutics Corporation the two are £0.0609 per share apart. That gap is exactly why we show both numbers side by side.
How much is CRISM Therapeutics Corporation worth?
The market values CRISM Therapeutics Corporation at about £6.8M (market capitalisation, as of Nov 4, 2026). Per share that is £0.0850; our models calculate a fair value of £0.0241 per share.
What do the bullish and bearish scenarios say about CRTX?
Our models span a range for CRISM Therapeutics Corporation: cautious scenario £0.0167, base £0.0241, optimistic £0.0241 per share (as of Nov 4, 2026, price £0.0850). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CRISM Therapeutics Corporation (CRTX)?
Balance-sheet figures for CRISM Therapeutics Corporation (as of Nov 4, 2026): return on equity −129.8%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is CRTX from its 52-week high?
CRISM Therapeutics Corporation trades at £0.0850, about 51% below its 52-week high of £0.1750 and at the low of £0.0850 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0241 is for.
Which stocks are comparable to CRISM Therapeutics Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CRISM Therapeutics Corporation stock attractive at the current price?
The data as of Nov 4, 2026: price £0.0850, calculated fair value £0.0241 (−72%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRTX calculated?
We run CRISM Therapeutics Corporation through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of £0.0241 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. CRISM Therapeutics Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CRISM Therapeutics Corporation (CRTX)?
The closing price on Nov 6, 2026 was £0.0850. Our model-based fair value is £0.0241, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CRISM Therapeutics Corporation right now?
The price sits above even our optimistic bull case (£0.0241). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CRISM Therapeutics Corporation

How large is the market capitalisation of CRISM Therapeutics Corporation (CRTX)?
The market capitalisation of CRISM Therapeutics Corporation is £6.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CRISM Therapeutics Corporation (CRTX)?
The price-to-sales ratio of CRISM Therapeutics Corporation is 32.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CRISM Therapeutics Corporation (CRTX)?
Earnings per share at CRISM Therapeutics Corporation are £−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CRISM Therapeutics Corporation (CRTX)?
The dividend yield of CRISM Therapeutics Corporation is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of CRISM Therapeutics Corporation (CRTX)?
The return on equity (ROE) of CRISM Therapeutics Corporation is −130% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CRISM Therapeutics Corporation (CRTX)?
On an EBIT basis the return on assets of CRISM Therapeutics Corporation is −42.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CRISM Therapeutics Corporation (CRTX)?
The operating margin of CRISM Therapeutics Corporation is −420% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does CRISM Therapeutics Corporation (CRTX) generate?
The free cash flow of CRISM Therapeutics Corporation is −£2.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CRISM Therapeutics Corporation (CRTX) hold?
CRISM Therapeutics Corporation holds more cash than debt, £1.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CRISM Therapeutics Corporation in the live analysis

One click puts CRISM Therapeutics Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.